At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 90 enrolled
Drug / intervention
SD-809 +1 moredrug
Likely dose
SD-809 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Feb 21, 2013·Updated Sep 20, 2017
In Brief
A Phase 3 clinical trial evaluating SD-809 and Placebo for Chorea. Completed, enrolled 90 participants across 43 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChorea
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartAug 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedFeb 21, 2013
Enrollment StartAug 5, 2013
Primary CompletionDec 5, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.4 years ago
Interventions
SD-809drug
SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
Placebodrug
Placebo tablets are identical in appearance to SD-809 tablets.